You may choose to receive automated email notifications when Humanigen publishes new press releases.
Click here to sign up for Humanigen PR alerts.

Published November 23, 2020

Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans

Published November 11, 2020

Humanigen Reports Third Quarter and Nine Months Ended September 30, 2020 Financial Results

Published November 6, 2020

Humanigen Announces Cooperative Research and Development Agreement with the U.S. government to Develop Lenzilumab for COVID-19

Published November 6, 2020

Humanigen Announces Positive Interim Phase 3 Data of Lenzilumab™ in Patients Hospitalized with COVID-19

Published November 4, 2020

Humanigen Announces ZUMA-19 Abstract Accepted for Presentation at American Society of Hematology 2020 Annual Meeting

Published November 3, 2020

Humanigen Executes Licensing Agreement for Lenzilumab™ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines

Published October 30, 2020

Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19

Published October 29, 2020

Humanigen Announces First Patient Dosed in NIH ACTIV-5/Big Effect Trial Evaluating Lenzilumab™ for COVID-19

Published October 27, 2020

Humanigen to Present at Upcoming Investor Conferences

Published October 13, 2020

National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy

©2020 Humanigen, Inc.  All rights reserved